Overview
- UKAEA is committing £5.6 million in equity, while TAE backs the effort with a nine‑figure internal investment to accelerate development and deployment.
- Operations will be based at UKAEA’s Culham Campus in Oxfordshire, with the partners highlighting plans to grow high‑skilled jobs and anchor a UK supply‑chain hub.
- Initial short‑pulse beams are planned in 18–24 months from work start, subject to customary regulatory approvals.
- TAE Beam UK will design, build and service neutral beam systems for multiple fusion approaches and adapt the accelerator platform for cancer therapy, food safety and homeland security, leveraging technology already used by TAE Life Sciences.
- TAE cites deep neutral‑beam experience on its own devices and longstanding private backing, including investors Google and Chevron and a $150 million round earlier this year.